Physician profile
Ellen Levan
NPI 1710960927
$3,685.93
in general payments reported to CMS, 2019-2025
25 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $652 · 2021: $604 · 2022: $550 · 2023: $476 · 2024: $542 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.57 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.87 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $318.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $317.56 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $298.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $295.92 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $265.39 | 2019-2024 | |
| Allergan, INC. | $171.03 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.24 | 2019-2021 | |
| Astellas Pharma US INC | $119.84 | 2019-2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $97.69 | 2019-2022 | |
| Exact Sciences Corporation | $48.19 | 2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $31.74 | 2022 | |
| Amarin Pharma, INC. | $29.79 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $28.72 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $28.43 | 2022 | |
| Avanir Pharmaceuticals, INC. | $27.27 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.04 | 2023 | Nuedexta |
| Vivus LLC | $17.00 | 2024 | Pancreaze |
| Amgen INC. | $15.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2021 | |
| Esperion Therapeutics, INC. | $12.60 | 2021 | |
| Merck Sharp & Dohme LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Levan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.